Artificial intelligence is reshaping how health care organizations support clinicians and, ultimately, how they care for patients. That transformation, however, is unfolding along two very different paths at the point of care.

In one model, adoption is clinician-driven. Tools are downloaded, tested, and incorporated into daily practice without formal enterprise involvement. This organic uptake often reflects real clinical need, especially in environments defined by time pressure and cognitive overload. But it can also result in inconsistent use, unclear standards, and limited visibility into what tools are influencing a clinician’s care decisions.

In the second model, point-of-care solutions are deployed at the enterprise level. These tools are integrated into workflows, governed through clinical and administrative oversight, and supported by the operational rigor designed for a regulated environment. Clinicians can gain fast, dependable access to trusted information. Administrators can gain the oversight, accountability, and traceability designed to manage risk at scale.

That distinction matters across clinical workflows and becomes decisive in one of the most sensitive areas of care: drug dosing.

Why drug dosing is different

Drug dosing is one of the most consequential areas of patient care. It’s an area that requires both clinical reasoning and judgment. Dosing decisions are shaped by patient-specific variables, including age, weight, renal and hepatic function, comorbidities, contraindications, and concurrent medications. Just as important, dosing needs traceability. Clinicians and organizations must be able to understand why a recommendation was made and what evidence supports it.

For many health care enterprises, AI-enabled drug dosing represents the third rail of point-of-care innovation. AI will never replace a doctor’s insight and decisions, but drug dosing raises the bar for trust, governance, and accountability.

In discussions with health system leaders, one theme consistently emerges: Tolerance for unreliable solutions is thin. They stress that drug dosing decisions by clinicians demand a high level of support, particularly when physicians may be making recommendations quickly and under pressure.

The enterprise questions that define trust

As health care organizations evaluate AI drug dosing at the enterprise level, several core questions quickly surface. These are not theoretical concerns. They are the practical criteria that determine whether a solution it selects promotes patient safety.

How reliable and complete is the data?

Enterprises need to know the source data. And where dosing information is sourced, it should note that it is evidence-based (and a link to that evidence), how current it is, and how updates are managed. Label changes, clinician safety communications, and evolving guidelines can materially alter recommended dosing. Any clinical AI system used in this context should demonstrate how it updates its content and how changes are governed over time.

How is clinical expertise encoded, and who stands behind it?

Drug dosing is not a generic language task. It requires the deliberate application of clinical expertise to real-world scenarios. Organizations want clarity on who develops the dosing recommendations, what qualifications they hold, and what editorial and clinical governance processes are in place. This includes how conflicting evidence is resolved and how complex cases, such as renal impairment or pediatric dosing, are handled. Trust depends on knowing that expertise is intentionally built into the system and continuously maintained.

Is sourcing transparent and easily verifiable?

In drug dosing, transparency is a safety requirement. Clinicians need to access recommendations quickly, and administrators need auditability. The standard is simple: With one click, can a clinician see the source behind the recommendation, including the guideline, label, or evidence excerpt and its date or version? Without this level of transparency, even a well-designed system can fail to earn clinical trust.

Does the AI reinforce clinical judgment rather than bypass it?

Enterprise leaders are increasingly focused on how AI systems interact with clinical reasoning. The most effective decision support tools prompt clinicians for missing context, surface contraindications and uncertainty, and explain rationale rather than presenting a single recommendation. In our view, AI should support thoughtful clinical decision-making, not shortcut it.

What is under the hood matters

Beyond content and workflow, enterprises are also asking harder questions about the technology itself. What model is being used? How has it been tested and verified for dosing scenarios? How is it challenged, monitored, and updated over time? What happens when performance degrades or errors are identified?

In high-risk clinical workflows, trust cannot be assumed. It must be continuously demonstrated through documented testing, clinical review of outputs, ongoing monitoring, and clear escalation paths. Especially for drug dosing, deploying AI without a validation and governance framework is not innovation. It could be exposure.

The bar for enterprise AI drug dosing

AI has the potential to meaningfully improve point-of-care decision support. But drug dosing demands the highest of standards. The solutions that succeed at the enterprise level will be those that deliver evidence-based data; encode clinically governed expertise; provide transparent, verifiable sourcing; and strengthen clinical judgment rather than replace it.

Drug dosing is the third rail because it forces health care organizations to confront the hardest questions first. Getting it right sets the standard for responsible AI adoption across clinical care.

Amanda Heidemann is the senior clinical content consultant for clinical effectiveness at Wolters Kluwer Health. She is board-certified in family medicine and clinical informatics, bringing her extensive experience to Wolters Kluwer and the UpToDate® team to work with health administrators and care organizations seeking clinical transformation and optimization of technology solutions. She is passionate about using technology to enhance the patient-physician relationship and to deliver high-quality health care. More about her professional background can be found on her LinkedIn profile.